Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.
Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, Schneider S, Hubmann M, Zellmeier E, Ksienzyk B, Jurinovic V, Pasalic Z, Kakadia PM, Dufour A, Graf A, Krebs S, Blum H, Sauerland MC, Büchner T, Berdel WE, Woermann BJ, Bornhäuser M, Ehninger G, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA. Herold T, et al. Among authors: berdel we. Blood. 2014 Aug 21;124(8):1304-11. doi: 10.1182/blood-2013-12-540716. Epub 2014 Jun 12. Blood. 2014. PMID: 24923295 Free article. Clinical Trial.
Remission induction therapy: the more intensive the better?
Büchner T, Hiddemann W, Berdel W, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Andreesen R, Balleisen L, Haase D, Eimermacher H, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A. Büchner T, et al. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S41-4. doi: 10.1007/s002800100305. Cancer Chemother Pharmacol. 2001. PMID: 11587366
Novel der(1)t(1;19) in two patients with myeloid neoplasias.
Tchinda J, Volpert S, Neumann T, Kennerknecht I, Ritter J, Büchner T, Berdel WE, Horst J. Tchinda J, et al. Among authors: berdel we. Cancer Genet Cytogenet. 2002 Feb;133(1):61-5. doi: 10.1016/s0165-4608(01)00505-2. Cancer Genet Cytogenet. 2002. PMID: 11890991
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. Büchner T, et al. Among authors: berdel we. J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133. J Clin Oncol. 2003. PMID: 14673036 Clinical Trial.
Multicolor karyotyping in acute myeloid leukemia.
Tchinda J, Volpert S, McNeil N, Neumann T, Kennerknecht I, Ried T, Büchner T, Serve H, Berdel WE, Horst J, Hilgenfeld E. Tchinda J, et al. Among authors: berdel we. Leuk Lymphoma. 2003 Nov;44(11):1843-53. doi: 10.1080/10428190310001603605. Leuk Lymphoma. 2003. PMID: 14738135 Review.
Risk-adapted therapy of AML: the AMLCG experience.
Kern W, Haferlach T, Schoch C, Sauerland MC, Heinecke A, Wörmann B, Berdel W, Büchner T, Hiddemann W. Kern W, et al. Ann Hematol. 2004;83 Suppl 1:S49-51. doi: 10.1007/s00277-004-0849-8. Ann Hematol. 2004. PMID: 15124669 Clinical Trial.
629 results